A new blog post coauthored by Schaeffer Center experts in Health Affairs finds that insurer preferences for biologic and biosimilar drugs adds cost and complicates the work of hospital pharmacists and physicians.
Other featured articles
“Vaccine Passport” Certification — Policy and Ethical Considerations
An analysis of the policy and ethical considerations of implementing vaccine passports broadly.
Palliative Care Works, So Why Is It Rarely Used? Follow the Money
Schaeffer Center expert Mireille Jacobson co-authored an op-ed in STAT examining why hospitals and health systems are not investing in palliative care despite research showing this type of therapy substantially improves outcomes for patients with serious illness.
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.